Top Brand
Salt CompositionPramipexole 3.15mg
Our Recommendation
Pramirol SR 3.15 Tablet
54+ trust this
WHO GMP Certified
54+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
Parkinson's disease / Restless leg syndrome
Customers also bought
More About Pramirol SR 3.15 Tablet
Benefits
In Parkinson's disease Pramirol SR 3.15 Tablet is effective in relieving symptoms of Parkinson's disease such as tremors, muscle stiffness, and difficulty moving. It increases the amount of a chemical called dopamine in the brain which helps in the coordination of body movements. This medicine can therefore enhance the quality of life by improving the ability to carry out daily functions in a better manner. In Restless leg syndrome Restless leg syndrome is a condition that causes an uncontrollable urge to move your legs, usually because of an uncomfortable sensation. It typically happens in the evening or nighttime hours when you're sitting or lying down. Moving or walking, that is change in posture, will control the unpleasant feeling temporarily. Pramirol SR 3.15 Tablet helps to relieve this uncomfortable urge and calms these sensations. Take it as advised by the doctor to get the maximum relief.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Pramirol SR 3.15 Tablet is to be taken with food.
How it works
Pramirol SR 3.15 Tablet works by increasing the action of dopamine, a chemical messenger that is needed to control movement in the brain.
Unsafe: Avoid consuming alcohol with Pramirol SR 3.15 Tablet as it is deemed unsafe.
Seek medical advice from your doctor: Pramirol SR 3.15 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Seek medical advice from your doctor: Pramirol SR 3.15 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. Pramirol SR 3.15 Tablet suppresses serum prolactin and may interfere with breastfeeding.
Not Safe: Pramirol SR 3.15 Tablet may cause side effects which could affect your ability to drive. Pramirol SR 3.15 Tablet can cause hallucinations (seeing, hearing or feeling things that are not there). This may affect your ability to drive.
Caution Advised: Pramirol SR 3.15 Tablet should be used with caution in patients with kidney disease. Dose adjustment of Pramirol SR 3.15 Tablet may be needed. Doctor consultation is advised.
Safe when prescribed by an expert: Pramirol SR 3.15 Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Pramirol SR 3.15 Tablet may not be needed in these patients. Doctor consultation is advised.
What if I forget to take it?
If you forget a dose of Pramirol SR 3.15 Tablet , simply continue with your regular schedule and do not take a double dose.
Manufacturer Address
Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India.
References
Aminoff MJ. Pharmacologic Management of Parkinsonism & Other Movement Disorders. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 475-76
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1140-41
Pramipexole dihydrochloride. Ridgefield, Connecticut: Boehringer Ingelheim International GmbH; 2010 (22 Jan. 2019)
Chaves RG, Lamounier JA. Breastfeeding and maternal medications. J Pediatr (Rio J). 2004;80(5 Suppl):S189-S198 (22 Mar. 2019)
Pramipexole. South Ruislip, Middlesex: Aurobindo Pharma - Milpharm Ltd.; 2012 (22 Mar. 2019)
Central Drugs Standard Control Organisation (CDSCO) (07 Aug. 2023)
Pramipexole dihydrochloride (05 Aug. 2023)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
